Visit CABLIVI at booth #445 during the 61st ASH Annual Meeting—December 7-10, 2019, Orlando, FL SAUS.CAPL.19.08.4682 09/19
Choose CABLIVI for added strength in the fight against aTTP—the first and only FDA-approved therapy for adults with aTTP in combination with PEX and immunosuppressive therapy1,2
CABLIVI is not indicated for pediatric use.
CABLIVI is contraindicated in patients with a previous severe hypersensitivity reaction to caplacizumab-yhdp or to any of its excipients. Hypersensitivity reactions have included urticaria.
The most common adverse reactions (>15% of patients) were epistaxis (29%), headache (21%) and gingival bleeding (16%).
Concomitant use of CABLIVI with any anticoagulant may increase the risk of bleeding. Assess and monitor closely for bleeding with concomitant use.
There are no available data on CABLIVI use in pregnant women to inform a drug associated risk of major birth defects and miscarriage.
CABLIVI (caplacizumab-yhdp) is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.